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ABSTRACT
OBJECTIVE: The objective of this selective Evidence Based Medicine review is to determine
whether or not Horse Antithymocyte Globulin (ATG) plus Cyclosporine (CsA) is the most
effective first-line therapy for patients with bone marrow failure disorders.
STUDY DESIGN: Review of two randomized control trials (RCTs) and one single-center
retrospective study, which were published between 2010 and 2013. All studies were published in
the English language.
DATA SOURCES: Two randomized control trials and one single-center retrospective study
published in peer-reviewed journals, which were found using PubMed.
OUTCOMES MEASURED: Each of the three trials measured the patient-oriented outcome of
overall survival. Shin et al also assessed failure free survival. Survival was measured at different
year markers after therapy between all three studies and also implemented the use of the Kaplan
Meier curve for overall survival.
RESULTS: Scheinberg et al (2011) was the only study which yielded statistically significant
data supporting Horse ATG plus CsA as the superior therapy for patients with bone marrow
failure disorders (p-value = 0.04). Both the Passweg et al (2010) and Shin et al (2013) studies
demonstrated inconclusive data, as the results in each study did not yield a statistically
significant difference between the three treatment modalities: Horse ATG plus CsA, Rabbit ATG
plus CsA, or Basic Supportive Care (BSC).
CONCLUSIONS: Results were inconclusive due to only one of the three studies demonstrating
data to support Horse Antithymocyte Globulin as the best initial treatment for patients with bone
marrow failure disorders.
KEY WORDS: Aplastic Anemia, Myelodysplastic Syndrome, Anti-Thymocyte Globulin,
Cyclosporine
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INTRODUCTION
Bone marrow failure disorders are acquired or inherited rare diseases in which one or all
cell lines of the bone marrow are affected: it fails to produce a sufficient supply of red blood
cells, white blood cells, and/or platelets.1 It is estimated that Aplastic Anemia affects 4 out of 1
million people in the United States per year, whereas Myelodysplastic syndromes affect more
than 15,000 people in the United States per year.1 There is no readily available data which
describes the annual healthcare costs nor annual healthcare visits for patients with these
conditions. However, a variety of factors influence these costs and healthcare visits because of
the very unique patient population. Factors that influence the number of healthcare visits include
out-patient clinic visits/follow-up appointments, emergency room visits, spontaneous hospital
admissions, and a patient’s comorbid conditions.2 With that being said, it is also difficult to
delineate an average price for the amount of care that goes into these patients. However, the
following studies in this selective Evidence Based Medicine review demonstrate one treatment
route in which costs are completely covered: clinical trials.
Although most cases of Aplastic Anemia and MDS are idiopathic, there are some theories
as to what may trigger or cause these conditions: chemotherapy, radiation therapy, benzene or
other toxic chemicals, and certain viral infections.1 Diagnosing these conditions is difficult
because the symptom presentation is so broad and may resemble other more benign illnesses.
Common symptomatology is due to a deficit in one or more of the blood cell lines. Red blood
cells (RBCs) are responsible for transporting oxygen throughout the body. A deficiency in RBCs
would produce symptoms including fatigue, weakness, pallor, and dyspnea. A deficiency in
platelets, which are responsible for clotting blood, may produce symptoms such as unexplained
bleeding/bruising and petechiae. White blood cells play a significant role with helping the body
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fight infection and foreign invaders; therefore, a deficit in these cells could cause fevers and/or
frequent infections.1,3
Treatment for both Aplastic Anemia and MDS depends on a variety of factors including
age of the patient, the patient’s general well-being, and the severity of the patient’s disease. One
option for patients with more mild forms of their disease is supportive care. The purpose of
supportive care is to help with the management of symptomatology to help with improvement in
quality of life; this includes blood transfusions and growth factor therapy. Immunosuppressive
therapy is another treatment modality which is reserved for patients with moderate to severe
disease who necessitate medicinal intervention. This includes polyclonal antibody therapy such
as Antithymocyte Globulin or oral immunosuppressants such as Cyclosporine or Mycophenolate
Mofetil. Chemotherapy and radiation is also an option, which can help with the destruction or
complete cessation of division of immature/defective blood cells. Finally, the gold standard
treatment for any bone marrow failure disorder is blood and bone marrow stem cell
transplantation to replace the damaged blood cell lines in the bone marrow.1 However, many
patients do not qualify for this treatment modality due to not having an adequately matched
donor or having their condition be too poor to tolerate the long process of a transplant.
Currently, there is no known or proven immunosuppressive cure for bone marrow failure
disorders, especially for those who cannot feasibly receive transportation, which is the only
know cure for these diseases;4 however the aforementioned treatment methods have helped to
improve symptoms, quality of life, and have prolonged the lifespan in patients who suffer from
these diseases.1 Horse ATG is being evaluated as a reliable first line therapy for patients with
bone marrow failure disorders who do not have matched bone marrow or stem cell donors.
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OBJECTIVE
The objective of this selective Evidence Based Medicine review is to determine whether
or not Horse Antithymocyte Globulin (ATG) plus Cyclosporine (CsA) is the most effective firstline therapy for patients with bone marrow failure disorders.
METHODS
The criteria for this selective Evidence Based Medicine review evaluates two randomized
control trials and one single-center retrospective study, which were chosen based on population,
intervention, comparison groups, and outcomes measured. The selected population of interest
was patients with bone marrow failure disorders, specifically Aplastic Anemia and
Myelodysplastic Syndrome. The intervention in these three studies was Horse Antithymocyte
Globulin combined with Cyclosporine. The treatment group whom received the aforementioned
intervention was compared to the experimental group who, based on the study, either received
Rabbit Antithymocyte Globulin with Cyclosporine or Basic Supportive Care. The outcomes
measured in each of these three studies was overall survival. One study also measured the
outcome of failure free survival.
The following keywords were entered and searched on PubMed to uncover articles
relevant to the clinical question that also included results consistent with patient oriented
outcomes. All articles were published in English between 2010 and 2013 in peer reviewed
journals. The inclusion criteria was as follows: at least two randomized control trials containing
patients with a diagnosis of either Aplastic Anemia or MDS published during or after the year
2010. The exclusion criteria were any of the aforementioned patients who had received prior
immunosuppressive therapies or who had severe comorbid conditions. The statistics used and
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reported in this study were p-values, numbers needed to treat (NNT), and confidence intervals
(CI).
Table 1 – Demographics and Characteristics of included studies
Study
Type
#
Age
Inclusion criteria
Exclusion criteria
W/D
Pts
(yrs)
Scheinberg4 RCT
120 2-77 -Aplastic Anemia
-Fanconi’s anemia
Not
(2011)
years with bone marrow diagnosis, evidence noted
of
cellularity <30%,
of clonal disorder or
age
plus two of the
cytogenetics, prior
following:
immunosuppressive
absolute neutrophil therapy, infection,
count less than
HIV, severe
500, platelet count comorbid
less than 20,000,
conditions, cancer
absolute
patients currently
reticulocyte count undergoing
less than 60,000
chemotherapy,
-Age > 2 years
pregnancy,
language barrier
-Weight > 12 kg
Passweg5
(2010)

RCT

88

> 18
years

-MDS diagnosis, Refractory anemia
with or without
sideroblasts or
with excess blasts
-Transfusion
dependence for
less than 24
months
-Age > 18 years
-Eastern
Cooperative
Oncology Group
performance status
>2

-Patients with
5
chronic
myelomonocytic
leukemia, refractory
anemia with
excessive blasts in
transformation,
secondary MDS, or
infection

Interventions
Horse ATG 40
mg/kg of body
weight/day x 4
days plus
Cyclosporine
10 mg/kg/day
x 6 months

Horse ATG 15
mg/kg x 5
days and oral
Cyclosporine
(CsA) x 180
days
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Shin6
(2013)

Single
99
center
retrospe
-ctive
study

> 15
years

-Adults with
Severe Aplastic
Anemia who
received first-line
therapy with horse
ATG or rabbit
ATG at Seoul St.
Mary’s Hospital
between February
2001 and May
2010

-Prior
immunosuppressive
therapy, bone
marrow findings
consistent with
MDS, or <15 years
of age

Not
noted

Horse ATG 15
mg/kg/day x 5
days plus
Cyclosporine
5-6 mg/kg/day
x as long as
patient was
responding nor
developing
renal
complications

OUTCOMES MEASURED
The outcomes in this selective Evidence-Based Medicine review are reported as patientoriented outcomes. The outcomes include overall survival, which was measured at different year
markings post ATG therapy depending on the study, and failure free survival measured 5 years
after ATG treatment.
The Scheinberg et al randomized control trial measured overall survival at 3 years in
Aplastic Anemia patients who received Horse ATG with CsA compared with overall survival at
3 years in those Aplastic Anemia patients who had received Rabbit ATG with CsA. Overall
survival at 3 years was determined using the Kaplan Meier curve which recorded the patients’
hematologic response at 6 months after treatment in both groups.4
The Passweg et al randomized control trial measured overall survival at 2 years in low to
intermediate risk myelodysplastic patients who received Horse ATG and CsA compared to the
overall survival at 2 years of low to intermediate risk MDS patients who received basic
supportive care.5
The Shin et al single center retrospective study measured overall survival and failure free
survival at 5 years in Severe Aplastic Anemia patients who received Horse ATG with CsA
compared to the survival of those who received Rabbit ATG plus CsA. The Kaplan Meier curve
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was for overall survival was used to determine the survival data by assessing complete
hematologic response at 3, 6, 12, and 18 months after ATG therapy in both groups.6
RESULTS
This selective evidence-based medicine review evaluates Horse Antithymocyte Globulin
(ATG) with Cyclosporine as a first line treatment for patients with bone marrow failure
disorders. The results of these studies were presented in dichotomous data. Two of these studies
were randomized control trials while one was a single-center retrospective study.4,5,6
Scheinberg et al4 is a randomized control trial which assessed the efficacy of Horse ATG
and CsA compared to Rabbit ATG and CsA in patients 2 years or older with treatment-naive
Aplastic Anemia. This study encompassed 120 participants divided evenly into 60 patients per
arm: 60 patients would receive Horse ATG and CsA (the treatment group) while the remaining
60 would receive Rabbit ATG and CsA. This study presented a variety of outcomes, but this
evidence based medicine review will focus on the patient oriented outcome of overall survival.
Survival was measured at 3 years post-ATG therapy using the Kaplan Meier curve for overall
survival. The Kaplan Meier curve data was determined based on hematologic response at 6
months after ATG therapy in both groups. The extent of hematologic response was determined
based on the return of blood counts to within normal ranges and having patients become
transfusion-independent. Overall survival at 3 years significantly differed between the two
treatment regimens as is evident from their respective confidence intervals: 96% of patients
survived in the Horse ATG and CsA group whilst only 76% of patients survived in the Rabbit
ATG and CsA group. As calculated by the results of the study, for every 5 patients receiving
horse ATG plus CsA, 1 more patient is going to survive than if Rabbit ATG plus CsA was given
initially (refer to Table 2 for NNT value). The difference between the two groups was
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represented with a p-value of 0.04, making the data reported in this study statistically significant,
and Horse ATG plus CsA the superior treatment option.
Table 2: Clinical Efficacy of Using Horse ATG plus CsA to treat Aplastic Anemia
Study
CER (rATG) EER (hATG)
RBI
ABI
Scheinberg et
76%
96%
26.3%
20%
al

NNT
5

CER – control event rate; EER – experimental event rate; RBI – relative benefit increase; ABI – absolute benefit increase; rATG
– rabbit ATG; hATG – horse ATG

Passweg et al5 is a randomized control trial which assessed the efficacy of Horse ATG
and CsA compared to Basic Supportive Care (BSC) in patients older than eighteen years of age
with a documented MDS diagnosis. This study encompassed 88 participants, 45 of which were
randomly assigned to receive Horse ATG and CsA while the remaining 43 were randomly
assigned to receive BSC. In this study, patients were permitted to cross over from the BSC group
to the Horse ATG and CsA group if their MDS progressed to a more advanced stage or if they
did not have a response with BSC after 6 months. This study qualified as a randomized control
trial because patients were randomly assigned to their respective treatment arms. The patient
oriented outcome measured in this study was overall survival, defined as “the time from trial
registration until death as a result of any cause.”2 Overall survival was measured 2 years after
treatment was administered. There was not much variability in the confidence intervals of overall
survival for the respective treatment groups, as a total of 40 deaths had occurred throughout the
study: 49% of the patients in the Horse ATG and CsA arm had survived, while 63% of the
patients in the BSC arm had survived. The difference between the two groups was represented
with a p-value of 0.828. As calculated by the results of the study, for every 7 patients receiving
horse ATG plus CsA, 1 fewer patient is going to survive than if BSC was given initially (refer to
Table 3 for NNT value). Thus, based on the p-value and confidence intervals reported in this
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study, there is no statistically significant difference between the use of Horse ATG plus CsA or
BSC in MDS patients as it pertains to 2-year survival.
Table 3: Clinical Efficacy of Using Horse ATG plus CsA to treat patients with MDS
Study
CER (BSC)
EER (hATG)
RBI
ABI
Passweg et al
63%
49%
-22.2%
-14%

NNT
-7

Shin et al6 is a single-center retrospective study which assessed the efficacy of Horse
ATG and CsA compared to Rabbit ATG and CsA in patients older than 15 years who received
Horse or Rabbit ATG as a first-line therapy for Aplastic Anemia. This study retrospectively
analyzed 99 participants, 46 of which were treated with Horse ATG plus CsA, while the
remaining 53 were treated with Rabbit ATG plus CsA. There were two patient-oriented
outcomes presented in the results including overall survival and failure free survival. Both of the
survival data was measured at 5 years post-ATG therapy using the Kaplan Meier curve for
overall survival. The Kaplan Meier curve data was determined based on the patient’s overall
complete hematologic response at 3, 6, 12, and 18 months after ATG therapy in both groups. The
extent of hematologic response was determined based on the return of blood counts to within
normal ranges and having patients become transfusion-independent. Overall survival and failure
free survival at 5 years did not display a significant difference between the two groups, which is
evident by the respective p-values: 0.460 for overall survival and 0.911 for failure free survival.
As calculated by the results of the study, for every 125 patients who received horse ATG plus
CsA, 1 more patient is going to survive overall than if Rabbit ATG plus CsA was given initially
(refer to Table 4 for NNT value). With the outcome of failure free survival, for every 6 patients
who received horse ATG plus CsA, 1 more patient will relapse or require additional systemic
therapy than if rabbit ATG plus CsA was given initially. Therefore, there is no statistically
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significant difference between the use of Horse ATG plus CsA or Rabbit ATG plus CsA in
Aplastic Anemia patients as it pertains to 5-year overall and failure free survival.
Table 4: Retrospective Clinical Analysis of Using Horse ATG plus CsA to treat patients with
Aplastic Anemia – Overall Survival and Failure Free Survival
CER (rATG) EER (hATG)
RBI
ABI
NNT
Overall
82.7%
83.5%
0.967%
0.8%
125
Survival
Failure Free
40.9%
26.1%
-36.2%
-14.8%
-6
Survival
DISCUSSION
Antithymocyte globulin (ATG) is a polyclonal immunoglobulin in which the antibodies
react with multiple T cell markers and other tissue antigens in order to induce
immunosuppression.5,7 It is believed that ATG works by decreasing the circulating T cells while
simultaneously regulating T cell activation.2 ATG is also very commonly used in combination
with other immunosuppressive agents, such as Cyclosporine, in order to increase its efficacy
(livertox). ATG is manufactured from the plasma of rabbits or horses which is then immunized
with human T cells. Both Horse and Rabbit ATG are FDA approved2 and commercially available
for use in the United States. ATG has been approved for use as an anti-rejection agent in solid
organ transplantation and as immunosuppressive therapy for Aplastic Anemia. There are also a
number off-label uses for ATG therapy,7 including its use in low to intermediate risk MDS
patients.5 When first administered, ATG can cause multiple side effects due to a variety of
reasons: the patient’s underlying condition, a foreign body immune response due to the animal
product component, or initial T cell encounter with the ATG antibodies within the first few days
of therapy. Side effects include serum sickness, anaphylaxis, high fever, dyspnea, nausea, chest
pain, and diarrhea.7

Miller, Horse ATG and Bone Marrow Failure Disorders 12	
  
While this selective Evidence Based Medicine review addresses the broader question of
whether or not Horse ATG is the best initial therapy for patients with bone marrow failure
disorders, the three studies included in this review actually address a further dimension to this
question: ATG therapy as initial treatment for patients who do not qualify for bone marrow or
stem cell transplantation. Each of the three studies displayed some evidence supporting ATG as a
first line therapy for patients who do not initially qualify for transplantation at the time of
diagnosis. Passweg et al reports that “stem cell transplantation is the only curative approach, but
is not feasible for most patients.”5 Therefore, this paper is reviewing the secondary treatment
option of Horse ATG plus CsA to transplantation for this patient population as another
potentially curative approach.
Although the data reported in each of the three studies demonstrated a varying degree of
statistical significance, there were small discrepancies which could have ultimately impacted the
results. In the Passweg et al5 study, one major limitation was the lack of an active comparator.
With an active comparator, the study was only able to establish that Horse ATG plus CsA was
better than no treatment at all, despite there being other immunosuppressive treatments available.
Another limitation, present in all of the involved studies, was the relatively small patient
population. However, the rarity of these diseases would make it rather difficult to conduct a
traditional large-scale study.
CONCLUSION
Scheinberg et al4 was the only one of the three studies presented in this selective
Evidence Based Medicine review that successfully supported the ultimate question. It
demonstrated that Horse ATG was, in fact, the superior immunosuppressive treatment of choice
for patients with bone marrow failure disorders who did not qualify for transplantation at the
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time of diagnosis. The remaining two articles provided inconclusive data regarding overall
survival where the depicted p-values represented insignificant results between Horse ATG plus
CsA compared to another treatment modality, including BSC and Rabbit ATG plus CsA.5,6 Due
to the inconsistency with data across the spectrum of these studies, further research would be
warranted to determine the initial immunosuppressive treatment of choice for patients with bone
marrow failure disorders who do not qualify for transplantation. In the future, it would also be
useful to create a study which compares the initial and superior immunosuppressive treatment to
transplantation in order to assess the overall efficacies of both treatment modalities. Therefore,
patients could ultimately benefit by weighing the benefits and risks of each treatment option.
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